Frontlight ResearchEarly access
Taking peopleNo phase
Impact of Chronic Pulmonary Aspergillosis (CPA) on Health Status and Well-being
Key facts
- Who runs it
- Imperial College London
- Where
- United Kingdom3 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 100 people, planned
- Started
- 27 Nov 2024
- Planned end
- 23 Apr 2026
- Type of study
- Observational
- Record updated
- 20 March 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- All patients >/= 18 years old and able to provide informed consent
- Patients with a diagnosis of chronic pulmonary aspergillosis
- To speak and understand English
- Able to provide informed consent
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
To develop and validate a novel disease-specific questionnaire for measuring HRQoL in patients with Chronic Pulmonary Aspergillosis (CPA-HAQ) for use in clinical research, including clinical trials.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 20 March 2025